Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma-Reference-Cited by-同舟云学术

Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma

Published:2017-10 Issue:10 Volume:16 Page:1705-1717
ISSN:1535-9476
Container-title:Molecular & Cellular Proteomics
language:en
Short-container-title:Molecular & Cellular Proteomics

Author:

Morales-Betanzos Carlos A.,Lee Hyoungjoo,Gonzalez Ericsson Paula I.,Balko Justin M.,Johnson Douglas B.,Zimmerman Lisa J.,Liebler Daniel C.

Funder

HHS NIH National Cancer Institute (NCI)

Publisher

Elsevier BV

Subject

Molecular Biology,Biochemistry,Analytical Chemistry

Reference59 articles.

1. PD-1 and its ligands in tolerance and immunity;Keir;Annu. Rev. Immunol,2008

2. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat. Rev. Cancer,2012

3. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial;Ribas;Lancet Oncol,2015

4. Pembrolizumab versus Ipilimumab in advanced melanoma;Robert;N. Engl. J. Med,2015

5. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma;Larkin;N. Engl. J. Med,2015

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N-linked glycosylation of PD-L1/PD-1: an emerging target for cancer diagnosis and treatment;Journal of Translational Medicine;2024-07-30

2. Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer;Clinical and Experimental Medicine;2024-07-18

3. Glycosylation and Its Role in Immune Checkpoint Proteins: From Molecular Mechanisms to Clinical Implications;Biomedicines;2024-06-28

4. 2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody (PART 1A – Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis PART 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine);Bioanalysis;2024-05-02

5. Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma;Cancer and Metastasis Reviews;2024-02-27